Roundview Capital’s BeOne Medicines Ltd ONC Stock Holding History

Roundview Capital’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,145	Closed	-$312K	–	335
2025 Q1	$312K	Buy	+1,145	New	+$268K	0.02%	280

Other funds holding ONC

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Roundview Capital's ONC Position: Q2 2025 in Review

Roundview Capital sold out of BeOne Medicines Ltd (ONC) in Q2 2025, closing a stake of 1,145 shares — an estimated $312K sold.

Roundview Capital first reported a position in ONC in Q1 2025 and held it in 1 quarter. The position peaked at $312K in Q1 2025. 244 funds tracked by Wall St. Rank hold ONC as of Q2 2025.

Roundview Capital reported no remaining BeOne Medicines Ltd position as of Q2 2025 after selling out during the quarter.
Roundview Capital sold 1,145 BeOne Medicines Ltd shares in Q2 2025, an estimated $312K.
Roundview Capital first reported a position in BeOne Medicines Ltd in Q1 2025 and held it in 1 quarter.
Roundview Capital's BeOne Medicines Ltd position peaked at $312K in Q1 2025.
244 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2025.

Based on Roundview Capital's 13F filing for Q2 2025, filed 23 Jul 2025.